GRI Bio, Inc.
GRI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.02 | -0.01 | 593.06 |
| FCF Yield | -333.69% | -34.77% | -0.25% | -0.01% |
| EV / EBITDA | 0.28 | -2.25 | -174.19 | -96,015.15 |
| Quality | ||||
| ROIC | -196.12% | -4,171.06% | 235.19% | -17.74% |
| Gross Margin | 48.41% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.05 | 0.70 | 0.34 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | 5.87% | -740.81% | 86.91% | -124.16% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 0.16 | -0.26 | 3.76 |
| Interest Coverage | 0.00 | -5.47 | -3.43 | -1.94 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -28.16 | 0.00 | 0.00 | 0.00 |